Evidence map›Paper›PMID 35037686›Full record

SynthesisBrain : a journal of neurology2022

Gene variant effects across sodium channelopathies predict function and guide precision therapy.

Andreas Brunklaus, Tony Feng, Tobias Brünger, Eduardo Perez-Palma, Henrike Heyne, Emma Matthews, Christopher Semsarian, Joseph D Symonds, Sameer M Zuberi, Dennis Lal and 1 more

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 100 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Elucidating the therapeutic targets and multi-target mechanisms of salvianolic acid A for diabetic nephropathy.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Gene therapies alleviate absence epilepsy associated withbioRxiv : the preprint server for biology · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Andreas BrunklausThe Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK.ORCID 0000-0002-7728-6903
Tony FengThe Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK.
Tobias BrüngerCologne Center for Genomics, University of Cologne, Cologne, Germany.
Eduardo Perez-PalmaCentro de Genética y Genómica, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
Henrike HeyneGenomic and Personalized Medicine, Digital Health Center, Hasso Plattner Institute, Potsdam, Germany.
Emma MatthewsAtkinson Morley Neuromuscular Centre, St George's University Hospitals NHS Foundation Trust, London, UK.
Christopher SemsarianAgnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia.
Joseph D SymondsThe Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK.ORCID 0000-0002-2141-4216
Sameer M ZuberiThe Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK.ORCID 0000-0002-4489-4697
Dennis LalEpilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, USA.
Stephanie SchorgeDepartment of Neuroscience, Physiology and Pharmacology, UCL, London, UK.
Royal Hospital for Children · GBBroad Institute · USHasso Plattner Institute · DESt George's, University of London · GBThe University of Sydney · AUUniversidad del Desarrollo · CLUniversity College London · GBUniversity of Cologne · DE

Funding

Agencia Nacional de Investigación y Desarrollo PAI77200124Dravet Syndrome Foundation 272016Dravet syndrome UK 16GLW00FamilieSCN2A foundation 2020 Action Potential GrantMedical Research Council MR/V037838/1National Health and Medical Research Council #1154992Wellcome Trust 209583/Z/17/Z
6 · The paper itself

Abstract

Pathogenic variants in the voltage-gated sodium channel gene family lead to early onset epilepsies, neurodevelopmental disorders, skeletal muscle channelopathies, peripheral neuropathies and cardiac arrhythmias. Disease-associated variants have diverse functional effects ranging from complete loss-of-function to marked gain-of-function. Therapeutic strategy is likely to depend on functional effect. Experimental studies offer important insights into channel function but are resource intensive and only performed in a minority of cases. Given the evolutionarily conserved nature of the sodium channel genes, we investigated whether similarities in biophysical properties between different voltage-gated sodium channels can predict function and inform precision treatment across sodium channelopathies. We performed a systematic literature search identifying functionally assessed variants in any of the nine voltage-gated sodium channel genes until 28 April 2021. We included missense variants that had been electrophysiologically characterized in mammalian cells in whole-cell patch-clamp recordings. We performed an alignment of linear protein sequences of all sodium channel genes and correlated variants by their overall functional effect on biophysical properties. Of 951 identified records, 437 sodium channel-variants met our inclusion criteria and were reviewed for functional properties. Of these, 141 variants were epilepsy-associated (SCN1/2/3/8A), 79 had a neuromuscular phenotype (SCN4/9/10/11A), 149 were associated with a cardiac phenotype (SCN5/10A) and 68 (16%) were considered benign. We detected 38 missense variant pairs with an identical disease-associated variant in a different sodium channel gene. Thirty-five out of 38 of those pairs resulted in similar functional consequences, indicating up to 92% biophysical agreement between corresponding sodium channel variants (odds ratio = 11.3; 95% confidence interval = 2.8 to 66.9; P < 0.001). Pathogenic missense variants were clustered in specific functional domains, whereas population variants were significantly more frequent across non-conserved domains (odds ratio = 18.6; 95% confidence interval = 10.9-34.4; P < 0.001). Pore-loop regions were frequently associated with loss-of-function variants, whereas inactivation sites were associated with gain-of-function (odds ratio = 42.1, 95% confidence interval = 14.5-122.4; P < 0.001), whilst variants occurring in voltage-sensing regions comprised a range of gain- and loss-of-function effects. Our findings suggest that biophysical characterisation of variants in one SCN-gene can predict channel function across different SCN-genes where experimental data are not available. The collected data represent the first gain- versus loss-of-function topological map of SCN proteins indicating shared patterns of biophysical effects aiding variant analysis and guiding precision therapy. We integrated our findings into a free online webtool to facilitate functional sodium channel gene variant interpretation (http://SCN-viewer.broadinstitute.org).

Indexed as

ChannelopathiesEpilepsyPeripheral Nervous System DiseasesVoltage-Gated Sodium ChannelsAnimalsMammalsPhenotypeVoltage-Gated Sodium ChannelsSCN1ASCN2ASCN4ASCN5ASCN8A

Identifiers

PMID35037686
PMCPMC9897196
OpenAlexW4205579581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.